Effects on montelukast treatment on clinical and inflammatory variables in patients with CF Stelmach, et al. Annals of Allergy, Astham and Immunology, Volume 95, Number 4, October 2005 pp. 372-380 (9)
In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.
There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.
Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).
Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.
In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.
There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.
Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).
Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.